Axsome Therapeutics (AXSM) Given a $13.00 Price Target at Cantor Fitzgerald

Axsome Therapeutics (NASDAQ:AXSM) has been given a $13.00 price objective by investment analysts at Cantor Fitzgerald in a research report issued on Friday, December 1st. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 173.68% from the company’s previous close.

Separately, Zacks Investment Research upgraded shares of Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research report on Tuesday, September 12th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.70.

Axsome Therapeutics (AXSM) opened at $4.75 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 3.86 and a current ratio of 3.86. Axsome Therapeutics has a 12-month low of $3.53 and a 12-month high of $7.20.

A number of institutional investors have recently added to or reduced their stakes in AXSM. Goldman Sachs Group Inc. purchased a new stake in Axsome Therapeutics during the first quarter valued at $121,000. LMR Partners LLP purchased a new stake in shares of Axsome Therapeutics in the second quarter valued at $206,000. Sphera Funds Management LTD. raised its stake in shares of Axsome Therapeutics by 24.9% in the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after acquiring an additional 100,000 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Axsome Therapeutics in the second quarter valued at $188,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Axsome Therapeutics by 1.6% in the third quarter. JPMorgan Chase & Co. now owns 1,459,117 shares of the company’s stock valued at $8,026,000 after acquiring an additional 23,229 shares during the period. 23.62% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Axsome Therapeutics (AXSM) Given a $13.00 Price Target at Cantor Fitzgerald” was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://weekherald.com/2017/12/13/cantor-fitzgerald-reiterates-13-00-price-target-for-axsome-therapeutics-axsm.html.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply